Tech Company Financing Transactions
Connect Biopharmaceuticals Funding Round
Connect Biopharmaceuticals secured a $20 million Series A financing round on 1/27/2017. Backers included Qiming Ventures, Northern Light Venture Capital and private investors.
Transaction Overview
Company Name
Announced On
1/27/2017
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Qiming Ventures (Lead Investor) (William Hu)
Proceeds Purpose
Proceeds from this financing will be used to support the upcoming Phase 2 clinical study of the company's lead drug candidate CBP-307 in patients with inflammatory bowel disease (IBD); and the IND-enabling and Phase 1 studies of a second drug candidate CBP-201 for the treatment of atopic dermatitis and asthma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4128 Viaduct Candidiz 145
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Suzhou Connect biopharma is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. We identify and advance our drug candidates through in-house discovery and in-licensing, while leveraging qualified CROs for further development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zheng Wei
Chief Financial Officer
Eric Hall
President
William Pan
Vice President
Lei Sun
Browse more venture capital transactions:
Prev: 1/27/2017: NeoGraft Technologies venture capital transaction
Next: 1/27/2017: Pypestream venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs